Activity of anti-erbB-2 recombinant toxin OLX-209 on lung cancer cell lines in the absence of erbB-2 gene amplification

Clinical Cancer Research

Volumn 2, Issue 1, 1996, Pages 75-80

  Kasprzyk, Philip G ^a,c   Sullivan, Terry L ^a,d   Hunt, Jay D ^b,e   Gubish, Christopher T ^a,b   Scoppa, Cathy A ^a,f   Oelkuct, Mark ^a,g   Bird, Robert ^a,h   Fischer, Paul H ^a,i   Siegfried, Jill M ^a,c   King, C Richter ^a,j  

^a Argonex Pharmaceuticals Inc   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c Biomeasure Inc   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^g GLAXOSMITHKLINE   (United States)

^h Microbiological Associates Inc   (United States)

ⁱ GENVEC INC   (United States)

^j GEORGETOWN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ONCOTOXIN OLX 209; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; GENE AMPLIFICATION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MOUSE; ONCOGENE NEU; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIBODIES; EXOTOXINS; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IMMUNOTOXINS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; RECOMBINANT FUSION PROTEINS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 9044224400     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bunn, P. A. Future directions in clinical research for lung cancer. Chest, 106 (Suppl. 6): 399S-407S, 1994.
2. neu) in human non-small cell carcinomas of the lung. Cancer Res., 50: 421-425, 1990.
3. neu expression in human lung carcinomas predicts shortened survival. Cancer Res., 50 5184-5191, 1990.
4. Shi, D., He, G., Cao, S., Pan, W., Zhang, H-Z., Yu, D., and Hung, M-C. Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. Mol. Carcinog., 5: 213-218, 1992.
5. Tateishi, M., Ishida, T., Mitsudomi, T., Kanedo, S., and Sugimachi, K. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur. J. Cancer. 27: 1372-1375, 1991.
6. Kern, J. A., Slebos, R. J. C., Top, B., Rodenhuis, S., Lager, D., Robinson, R. A., Weiner, D., and Schwartz, D. A. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J. Clin. Invest., 93: 516-520, 1994.
7. King, C. R., Kraus, M. H., and Aaronson, S. A Amplification of a novel v-erbB related gene in a human mammary carcinoma. Science (Wash. DC), 229: 974-976, 1985.
8. Slamon, D J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Wash. DC), 235: 177-182, 1987.
9. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and Press, M. F. Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science (Wash. DC), 244: 707-712, 1989.
10. HER2 expression in human non-small cell lung cancer cell lines. Am. J. Respir. Cell. Mol. Biol., 6: 359-363, 1992.
11. Suen, T-C., and Hung, M-C. Multiple cis- and trans-acting elements involved in regulation of the neu gene. Mol. Cell. Biol., 10: 6306-6315, 1990.
12. Hollywood, D P., and Hurst, H. C. A novel transcription factor OB2-1 is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour cell lines. EMBO (Eur. Mol. Biol. Organ.) J., 12: 2369-75, 1992.
13. Scott, G. K., Daniel, J. C., Xiong, X., Maki, R. A., Kabat, D., and Benz, C. C. Binding of an ETS-related protein within the DNase-I hypersensitivity site of the HER-2/neu promoter in human breast cancer cells. J. Biol. Chem., 269: 19848-58, 1994.
14. Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S-M , Lee, T., Pope, S. H , Riordan, G. S., and Whitlow, M. Single-chain antigen binding proteins. Science (Wash. DC), 242: 423-426, 1988.
15. Batra, J. K., Kasprzyk, P. G., Bird, R. E., Pastan, I., and King, C. R. Recombinant anti-erbB-2 immunotoxins containing Pseudomonas exotoxin. Proc. Natl. Acad. Sci. USA, 89: 5867-5871, 1992.
16. Kasprzyk, P. G., Song, S. U., Di Fiore, P. P., and King, C. R. Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res., 52: 2771-2776, 1992.
17. Reiter, Y., Brinkman, U., Jung, S-H , Lee, B., Kasprzyk, P. G., King, C. R., and Pastan, I. Improved binding and antitumor activity of a recombinant anti-erbB-2 immunotoxin by disulfide stabilization of the Fv fragment. J. Biol. Chem., 269: 18327-18331, 1994.
18. Levitt, M. L., Gazdar, A. F., Oie, H. K., Schuller, H., and Thacher, S. M. Cross-linked envelope-related markers for squamous differentiation in human lung cancer cell lines. Cancer Res., 50: 120-128, 1990.
19. Siegfried, J. M., and Owens, S. E. Response of primary human lung carcinomas to autocrine growth factors produced by a lung carcinoma cell line. Cancer Res., 48: 4976-4981, 1988
20. DeMichele, M. A., Davis, A. L., Landreneau, R. J., and Siegfried, J. M. Expression of mRNA for three bombesin receptor subtypes in human bronchial epithelial cells. Am. J. Respir. Cell. Mol. Biol., 11: 66-74, 1994.
21. Stegall, C. B., Chaudhary, V. K., Fitzgerald, D. J., and Pastan, I. Functional analysis of domains, II, Ib, and III of Pseudomonas exotoxin. J. Biol. Chem., 264: 14256-14261, 1989.
22. Chaudhary, V. K., Jinno, Y., Fitzgerald, D , and Pastan, I. Pseudomonas exotoxin contains a specific sequence at the carboxy terminus that is required for cytotoxicity. Proc Natl. Acad. Sci. USA, 87: 308-312, 1990.
23. Fischer, P. H., Bird, R. E., Kasprzyk, P. G., King, C. R., Turner, N. A., Pastan, I., Kihara, A., and Batra, J. In vitro and in vivo activity of a recombinant toxin, OLX-209, which targets the erbB-2 oncoprotein. Adv. Enzyme Regul., 34, 119-128, 1994.
24. Scott, P. A., and Harris, A. L. Current approaches to targeting cancer using angiogenesis therapies. Cancer Treat. Rev., 20: 393-412, 1994.
25. Callahan, R., and Salomon, D. S. Oncogenes, tumour suppressor genes and growth factors in breast cancer: novel targets for diagnosis, prognosis and therapy. Cancer Surv., 18: 1-5, 1993.
26. Coombes, R. C. New targets for cancer therapy. Mol. Aspects Med. 14: 373-449, 1993
27. Mendelsohn, J. Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. Natl. Cancer Inst. Monogr., 13: 125-131, 1992.